Basic mechanisms in intracranial large-artery atherosclerosis: Advances and challenges

Cerebrovascular Diseases

Volumn 20, Issue SUPPL. 2, 2005, Pages 75-83

  Arenillas Lara, Juan F ^a   Álvarez Sabín, José ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Angiogenesis; Atherosclerosis; C reactive protein; Diabetes mellitus; Endostatins; Inflammation; Intracranial; Intracranial stenosis; Lipoprotein(a)

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOSTATIN; VASCULOTROPIN; WARFARIN;

ANGIOGENESIS; ANGIOGRAPHY; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; DIABETES MELLITUS; DISEASE COURSE; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; INTRACRANIAL LARGE ARTERY ATHEROSCLEROSIS; LIPOPROTEIN BLOOD LEVEL; OVARY INFLAMMATION; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; CEREBROVASCULAR DISEASE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; REVIEW;

ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISORDERS; HUMANS; INFLAMMATION; NEOVASCULARIZATION, PATHOLOGIC;

EID: 33644815359     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089359     Document Type: Conference Paper

References (80)

1. Huang YN, Gao S, Li SW, Huang Y, Li JF, Wong KS, Kay R: Vascular lesions in Chinese patients with transient ischemic attacks. Neurology 1997;48:524-525.
2. Wong KS, Huang YN, Gao S, Lam WWM, Chan YL, Kay R: Intracranial stenosis in Chinese patients with acute stroke. Neurology 1998;50:812-813.
3. Sacco R, Kargman DE, Quiong Gu, Zamanillo MC: Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study. Stroke 1995;26:14-20.
4. Wityk RJ, Lehman D, Klag M, Coresh J, Ahn H, Litt B: Race and sex differences in the distribution of cerebral atherosclerosis. Stroke 1996;27:1974-1980.
5. Arenillas JF, Molina CA, Chacón P, Rovira A, Montaner J, Coscojuela P, Sánchez E, Quintana M, Álvarez-Sabín J: High lipoprotein(a), diabetes and the extent of symptomatic intracranial atherosclerosis. Neurology 2004;63:27-32.
6. Caplan LR, Gorelick PB, Hier DB: Race, sex and occlusive cerebrovascular disease: a review. Stroke 1986;17:648-655.
7. Gorelick PB, Caplan LR, Hier DB, Parker SL, Patel D: Racial differences in the distribution of anterior circulation occlusive disease. Neurology 1984;34:54-59.
8. Gorelick PB, Caplan LR, Hier DB, Patel D, Langenberg P, Pessin MS, Biller J, Kornack D: Racial differences in the distribution of posterior circulation occlusive disease. Stroke 1985;16:785-790.
9. Feldmann E, Daneault N, Kwan E, Ho KJ, Pessin MS, Langenberg P, Caplan LR: Chinese-white differences in the distribution of occlusive cerebrovascular disease. Neurology 1990;40:1541-1545.
10. Samuels OB, Joseph GJ, Lynn MJ, Smith HA, Chimowitz MI: A standardized method for measuring intracranial arterial stenosis. AJNR Am J Neuroradiol 2000;21:643-646.
11. Aaslid R, Markwalder TM, Nornes H: Noninvasive transcranial Doppler ultrasound recording of flow velocity in basal cerebral arteries. J Neurosurg 1982;57:769-774.
12. Lindegaard K-F, Bakke SJ, Aaslid R, Nornes H: Doppler diagnosis of intracranial occlusive disorders. J Neurol Neurosurg Psychiatry 1986;49:510-518.
13. Ley-Pozo J, Ringelstein EB: Noninvasive detection of occlusive disease of the carotid siphon and middle cerebral artery. Ann Neurol 1990;28:640-647.
14. Baumgartner RW, Mattle HP, Schroth G: Assessment of ≥ 50% or <50% intracranial stenoses by transcranial color-coded duplex sonography. Stroke 1999;30:87-92.
15. Fürst G, Hofer M, Steinmetz H, Kambergs J, Paselk C, Liebsch D, Aulich A, Modder U: Intracranial stenoocclusive disease: MR angiography with magnetization transfer and variable flip angle. AJNR Am J Neuroradiol 1996;17:1749-1757.
16. Korogi Y, Takahashi M, Mabuchi N, Miki H, Shiga H, Watabe T, O'Uchi T, Nakagawa T, Horikawa Y, Fujiwara S, Furuse M: Intracranial vascular stenosis and occlusion: diagnostic accuracy of three-dimensional, Fourier transform, tone-of-flight MR angiography. Radiology 1994;193:187-193.
17. Skutta B, Fürst G, Eilers J, Ferbert A, Kuhn FP: Intracranial stenoocclusive disease: double-detector helical CT angiography versus digital substraction angiography. Radiology 1999;20:791-799.
18. Suwanwela NC, Phanthumchinda K, Suwanwela N: Transcranial Doppler sonography and CT angiography in patients with atherothrombotic middle cerebral artery stroke. AJNR Am J Neuroradiol 2002;23:1352-1355.
19. Kiechl S, Willeit J; for the Brunneck Study Group: The natural course of atherosclerosis. I. Incidence and progression. Arterioscler Thromb Vasc Biol 1999;19:1484-1490.
20. Bogousslavsky J, Barnett HJ, Fox AJ, Hachinski VC, Taylor W: For the EC/IC Bypass Study Group. Atherosclerotic disease of the middle cerebral artery. Stroke 1986;17:1112-1120.
21. Marzewski DJ, Furlan AJ, St. Louis P, Little JR, Modic MT, Williams G: Intracranial internal carotid artery stenosis: long term prognosis. Stroke 1982;13:821-824.
22. The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study Group: Prognosis of patients with symptomatic vertebral or basilar artery stenosis. Stroke 1998;29:1389-1392.
23. Thijs VN, Albers GW: Symptomatic intracranial atherosclerosis. Outcome of patients who fail anithrombotic theraphy. Neurology 2000;55:490-497.
24. Arenillas JF, Alvarez-Sabín J, Molina C, Chacón P, Rovira A, Montaner J, Ibarra B, Quintana M: C-reactive protein predicts further ischemic events in first-ever TIA and stroke patients with intracranial large-artery occlusive disease. Stroke 2003;34:2463-2470.
25. Chimowitz MI; for the WASID Investigators: Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) trial: final results. Stroke 2004;35:235.
26. Akins PT, Pilgram TK, Cross III DT, Moran CJ: Natural history of stenosis from intracranial atherosclerosis by serial angiography. Stroke 1998;29:433-438.
27. Azen SP, Mack WJ, Cashin-Hemphill L, La-Bree L, Shircore AM, Selzer RH, Blankenhorn DH, Hodis HN: Progression of coronary artery disease predicts clinical coronary events. Circulation 1996;93:34-41.
28. Arenillas JF, Molina CA, Montaner J, Abilleira S, González- Sánchez MA, Álvarez-Sabín J: Progression and clinical recurrence of symptomatic middle cerebral artery stenosis. A long-term follow-up transcranial Doppler ultrasound study. Stroke 2001;32:2898-2904.
29. Wong KS, Li H, Lam WW, Chan YL, Kay R: Progression of middle cerebral artery occlusive disease and its relationship with further vascular events after stroke. Stroke 2002;33:532-536.
30. Wong KS, Li H, Chan YL, Ahuja A, Lam WWM, Wong A, Kay R: Use of transcranial Doppler ultrasound to predict outcome in patients with intracranial large-artery occlusive disease. Stroke 2000;31:2641-2647.
31. Wong KS, Li H: Long-term mortality and recurrent stroke risk among Chinese stroke patients with predominant intracranial atherosclerosis. Stroke 2003;34:2361-2366.
32. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126.
33. Libby P, Ridker P, Maseri A: Inflammation and atherosclerosis. Circulation 2002;105:1135-1143.
34. Lammie GA, Sandercock PA, Dennis MS: Recently occluded intracranial and extracranial carotid arteries. Relevance of the unstable atherosclerotic plaque. Stroke 1999;30:1319-1325.
35. Lhermitte F, Gautier JC, Derouesne C, Guiraud B: Ischemic accidents in the middle cerebral artery territory: a study of causes in 122 cases. Arch Neurol 1968;19:248-256.
36. Castaigne P, Lhermitte F, Gautier JC, Escourolle R, Derouesne C, Der Agopian P, Popa C: Arterial occlusions in the vertebro-basilar system. A study of 44 patients with post-mortem data. Brain 1973;96:133-154.
37. Caplan L: Posterior circulation ischemia: then, now, and tomorrow. The Thomas Willis Lecture-2000. Stroke 2000;31:2011-2023.
38. Schumacher HC, Tanji K, Mangla S, Meyers P, Pile-Spellman J, Hays AP, Mohr JP: Histopathological evaluation of middle cerebral artery after percutaneous intracranial transluminal angioplasty. Stroke 2003;34:170-173.
39. Ogata J, Masuda J, Yutani C, Yamaguchi T: Mechanisms of cerebral artery thrombosis: a histopathological analysis on eight necropsy cases. J Neurol Neurosurg Psychiatry 1994;57:17-21.
40. Wong KS, Gao S, Chan YL, Hansberg T, Lam WW, Droste DW, Kay R, Ringelstein EB: Mechanisms of acute cerebral infarctions in patients with middle cerebral artery stenosis: a diffusion-weighted imaging and microemboli monitoring study. Ann Neurol 2002;52:74-81.
41. Segura T, Serena J, Castellanos M, Teruel J, Vilar C, Dávalos A: Embolism in acute middle cerebral artery stenosis. Neurology 2001;56:497-501.
42. Arenillas JF, Alvarez-Sabín J, Montaner J, Rosell A, Molina CA, Rovira A, Ribo M, Sánchez E, Quintana M: Angiogenesis in symptomatic intracranial atherosclerosis: predominance of the inhibitor endostatin is related to a greater extent and risk of recurrence. Stroke 2005;36:92-97.
43. Fassbender K, Bertsch T, Mielke O, Mühlhauser F, Hennerici M: Adhesion molecules in cerebrovascular diseases. Evidence for an inflammatory endothelial activation in cerebral large- and small-vessel disease. Stroke 1999;30:1647-1690.
44. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH: Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-733.
45. Koenig W, Sund M, Fröhlich M, Fisher H-G, Löwel H, Döring A, Hutchinson W, Pepys MB: C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Circulation 1999;99:237-242.
46. Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, Silbershatz H, Massaro JM, D'Agostino RB, Franzblau C, Wilson PWF: Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack. The Framingham study. Stroke 2001;32:2575-2579.
47. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, Summaria F, Ginnetti F, Fadda, Maseri A: Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999;99:855-860.
48. Muir KW, Weir CJ, Alwan W, Squire IB, Lees KR: C-reactive protein and outcome after ischemic stroke. Stroke 1999;30:981-985.
49. Di Napoli M, Papa F, Bocola V: C-reactive protein in ischemic stroke. An independent prognostic factor. Stroke 2001;32:917-924.
50. Winbeck K, Poppert H, Etgen T, Conrad B, Sander D: Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke 2002;33:2459-2464.
51. Hashimoto H, Kitagawa K, Hougaku H, Shimizu Y, Sakaguchi M, Nagai Y, Iyama S, Yamanishi H, Matsumoto M, Hori M: C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation 2001;104:63-67.
52. Van der Meer IM, de Maat MPM, Hak AE, Kiliaan AJ, Iglesias del Sol A, van der Kuip DAM, Nijhuis RLG, Hofman A, Witteman JCM: C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree. The Rotterdam study. Stroke 2002;33:2750-2755.
53. Sano T, Tanaka A, Namba M, Nishibori Y, Nishida Y, Kawarabayashi T, Fukuda D, Shimada K, Yoshikawa J: C-reactive protein and lesion morphology in patients with acute myocardial infarction. Circulation 2003;108:282-285.
54. Torzewski J, Torzewski M, Bowyer DE, Fröhlich M, Koenig W, Waltenberger J, Flitzsimmons C, Hombach V: C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998;18:1386-1392.
55. Verma S, Wang C-H, Li S-H, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li R-K, Mickle DA, Stewart DJ: A self-fulfilling prophecy. C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913-919.
56. Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger, Koenig W, Schmitz G, Hombach V, Torzewski J: C-reactive protein in the arterial intima. Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000;20:2094-2099.
57. Pasceri V, Willerson JT, Yeh ETH: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-2168.
58. Nakagomi A, Freedman B, Geczy CL: Interferon-γ and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein. Relationship with age, sex, and hormone replacement treatment. Circulation 2000;101:1785-1791.
59. 9 Devaraj S, Xu DY, Jialal I: C-reactive protein increases plasminogen activator inhibitor expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherosclerosis. Circulation 2003;28:398-404.
60. Lam WW, Wong KS, So NM, Yeung TK, Gao S: Plaque volume measurement by magnetic resonance imaging as an index of remodelling of middle cerebral artery: Correlation with transcranial color Doppler and magnetic resonance angiography. Cerebrovasc Dis 2004;17:166-169.
61. Marti H, Risau W: Angiogenesis in ischemic disease. Thromb Haemost 1999;82:44-52.
62. Rosell-Novel A, Montaner J, Alvarez-Sabín J: Angiogenesis in human cerebral ischemia. Rev Neurol 2004;38:1076-1082.
63. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309.
64. Zhang ZG, Zhang L, Jiang Q, Zhang R, Davies K, Powers C, van Bruggen N, Chopp M: VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 2000;106:829-838.
65. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
66. Issa R, Krupinski J, Bujny T, Kumar S, Kaluza J, Kumar P: Vascular endothelial growth factor and its receptor, KDR, in human brain tissue after ischemic stroke. Lab Invest 1999;79:417-425.
67. 165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998;97:1114-1123.
68. Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergmann GW, Hachamovitch R, Szulc M, Kligfield PD, Okin PM, Hahn RT, Devereux RB, Post MR, Hackett NR, Foster T, Grasso TM, Lesser ML, Isom OW, Crystal RG: Angiogenesis gene therapy. Phase I assessment of direct intramyocardial administration of an adenovirus vector ex-pressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999;100:468-474.
69. Celetti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD: Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001;7:425-429.
70. Hutter R, Sauter BV, Reis ED, Roque M, Vorchheimer D, Carrick FE, Fallon JT, Fuster V, Badimon JJ: Decreased reendothelialization and increased neointima formation with endostatin overexpression in a mouse model of arterial injury. Circulation 2003;107:1658-1663.
71. Utermann G: The mysteries of lipoprotein(a). Science 1989;246:904-910.
72. Miles LA, Fless GM, Levin EG, Scann AM, Plow EF: A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989;339:301-303.
73. Hajjar KA, Gavish D, Breslow JL, Nachman RL: Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339:303-305.
74. Pedro-Botet J, Senti M, Nogues X, Rubies-Prat, Roquer J, D'Olhaberriague L, Olive J: Lipoprotein and apolipoprotein profile in men with ischemic stroke. Role of lipoprotein(a), triglyceride-rich lipoproteins, and apolipoprotein E polymorphism. Stroke 1992;23:1556-1562.
75. Ariyo AA, Thach C, Tracy R; Cardiovascular Health Study Investigators: Lp(a) lipoprotein, vascular disease and mortality in the elderly. N Engl J Med 2003;349:2108-2115.
76. Armstrong VW, Cremer P, Eberle E, Manke A, Schulze F, Wieland H, Kreuzer H, Seidel D: The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Atherosclerosis 1986;62:249-257.
77. Jurgens G, Taddei-Peters WC, Koltringer P, Petek W, Chen Q, Greilberger J, Macomber PF, Butman BT, Stead AG, Ransom JH: Lipoprotein(a) serum concentration and apolipoprotein (a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke 1995;26:1841-1848.
78. Sutton-Tyrrell K, Evans RW, Meilahn E, Alcorn HG: Lipoprotein(a) and peripheral atherosclerosis in older adults. Atherosclerosis 1996;122:11-19.
79. Mendes I, Baptista P, Soares F, Oliveira V, Ferro JM: Diabetes mellitus and intracranial stenosis. Rev Neurol 1999;28:1030-1033.
80. Hernández C, Chacón P, García-Pascual L, Mesa J, Simó R: Relationship between lipoprotein(a) phenotypes and plasminogen activator inhibitor type 1 in diabetic patients. Thromb Res 2000;99:118-127.